Universität zu Köln

Wehmeier, Peter M., Schacht, Alexander, Ulberstad, Fredrik, Lehmann, Martin, Schneider-Fresenius, Christian, Lehmkuhl, Gerd, Dittmann, Ralf W. and Banaschewski, Tobias ORCID: 0000-0003-4595-1144 (2012). Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity? Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology. J. Clin. Psychopharmacol., 32 (5). S. 653 - 661. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1533-712X

Full text not available from this repository.

Abstract

The primary objective of this study was to evaluate the efficacy of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD)-related symptoms assessed as standard variables of a computer-based continuous performance test (cb-CPT) combined with a motion-tracking (MT) device. This was a 2-arm, 8-week, randomized, double-blind, placebo-controlled study in patients with ADHD (6-12 years). Therapy with ATX started with 0.5 mg/kg per day for 1 week, followed by 7 weeks on the target dosage of 1.2 mg/kg per day. Primary outcomes were cb-CPT/MT standard scores after 8 weeks using mixed models for repeated measurements. In addition, investigator-rated ADHD Rating Scale (ADHD-RS), Weekly Ratings of Evening and Morning Behavior (WREMB), and Clinical Global Impression - Severity-ADHD (CGI-S-ADHD) scores were assessed. Of 128 patients randomized, 125 were evaluated (ATX/placebo: 63/62). Baseline characteristics were comparable in both groups (overall, 80.2% boys; mean [SD] age, 9.0 [1.79] years; comorbid Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis, 40.0% oppositional defiant disorder/conduct disorder; prior stimulant treatment, 24.8%; ADHD-RS total score, 36.99 [11.56]). At week 8, all cb-CPT/MT q-scores were significantly reduced versus placebo (all P < 0.001) with effect sizes (ESs) of reaction time (RT) variation (ES = 0.71), mean RT (ES = 0.41), number of microevents (ES = 1.00), commission error rate (ES = 0.50), distance of movement (ES = 0.90), area of movement (ES = 1.08), omission error rate (ES = 0.70), time active (ES = 0.69), motion simplicity (ES = 0.38), and normalized variance of RT (ES = 0.50). Secondary end points also improved significantly in favor of ATX: ADHD-RS (total score ES = 1.30, P < 0.001; hyperactivity/impulsivity subscore ES = 1.37, P < 0.001; inattention subscore ES = 1.07, P < 0.001), WREMB (total score ES = 1.00, P < 0.001; morning subscore ES = 0.59, P = 0.002; evening subscore ES = 1.02, P < 0.001), CGI-S-ADHD (ES = 1.11, P < 0.001). The results of this study show that ATX for 8 weeks significantly reduced ADHD-related symptoms as measured by the cb-CPT/MT.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wehmeier, Peter M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schacht, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Ulberstad, Fredrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneider-Fresenius, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmkuhl, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Dittmann, Ralf W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Banaschewski, Tobias UNSPECIFIED orcid.org/0000-0003-4595-1144 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-482467
DOI:	10.1097/JCP.0b013e318267c304
Journal or Publication Title:	J. Clin. Psychopharmacol.
Volume:	32
Number:	5
Page Range:	S. 653 - 661
Date:	2012
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1533-712X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CONTINUOUS PERFORMANCE-TEST; OBJECTIVE MEASUREMENT; MOTOR-ACTIVITY; CHILDREN; INATTENTION; ADHD; IMPULSIVITY; STIMULANTS; MEDICATION Multiple languages Pharmacology & Pharmacy; Psychiatry Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/48246